XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b study (X-TOLE) in Adults with Focal Epilepsy

被引：1

作者：

French, Jacqueline ^{[1
]}

Porter, Roger ^{[2
]}

Perucca, Emilio ^{[3
]}

Brodie, Martin ^{[4
]}

Rogawski, Michael ^{[5
]}

Harden, Cynthia ^{[6
,7
]}

Qian, Jenny ^{[7
]}

Luzon-Rosenblut, Constanza ^{[7
]}

Kenney, Christopher ^{[7
]}

Beatch, Gregory ^{[7
]}

机构：

[1] New York Univ, NYU Langone Hlth, Grossman Sch Med, New York, NY USA

[2] Univ Penn, Philadelphia, PA USA

[3] Monash Univ, Melbourne, Vic, Australia

[4] Univ Melbourne, Australia & Austin Hlth, Heidelberg, Vic, Australia

[5] Univ Glasgow, Glasgow, Lanark, Scotland

[6] Univ Calif Davis, Sacramento, CA USA

[7] Xenon Pharmaceut Inc, Burnaby, BC, Canada

来源：

NEUROLOGY | 2023年 / 100卷 / 17期

关键词：

D O I：

10.1212/WNL.0000000000203823

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

S44.008

引用

页数：7

共 50 条

[1] XEN1101, a novel potassium channel modulator: interim data from an ongoing, long-term, open-label extension of a phase 2b study (X-TOLE) in adults with focal epilepsy
French, J.
Porter, R.
Perucca, E.
Brodie, M.
Rogawski, M. A.
Harden, C.
Qian, J.
Luzon-Rosenblut, C.
Kenney, C.
Beatch, G. N.
EPILEPSIA, 2023, 64 : 275 - 276
[2] XEN1101, a novel, potent potassium channel modulator: Interim data from an ongoing, long-term, open-label extension of a Phase 2b study (X-TOLE) in adults with focal onset seizures (FOS)
French, J.
Porter, R.
Perucca, E.
Brodie, M.
Rogawski, M. A.
Harden, C.
Qian, J.
Rosenblut, C. Luzon
Kenney, C.
Beatch, G. N.
EPILEPSIA, 2024, 65 : 184 - 184
[3] Phase 2B Efficacy and Safety of XEN1101, a Novel Potassium Channel Modulator, In Adults with Focal Epilepsy (X-TOLE)
French, Jacqueline
Porter, Roger
Perucca, Emilio
Brodie, Martin
Rogawski, Michael A.
Pimstone, Simon
Aycardi, Ernesto
Harden, Cynthia
Xu, Yi
Rosenblut, Constanza Luzon
Kenney, Christopher
Beatch, Greg
NEUROTHERAPEUTICS, 2022, 19 (04) : 1427 - 1427
[4] Quality- of- life improvements in adults with focal onset seizures treated with XEN1101 in an ongoing, long-term, open-label extension of a phase 2b study (X-TOLE)
Brandt, C.
Villanueva, V.
Harden, C.
Qian, J.
Luzon-Rosenblut, C.
Wagner, J.
Kenney, C.
Beatch, G. N.
EPILEPSIA, 2023, 64 : 276 - 276
[5] Rapid onset of efficacy of XEN1101, a novel potassium channel opener, in adults with focal epilepsy: Results from a phase 2b study (X-TOLE)
Kenney, C.
French, J.
Porter, R.
Perucca, E.
Brodie, M.
Rogawski, M.
Harden, C.
Rosenblut, C. Luzon
Qian, J.
Leung, J.
Beatch, G.
EPILEPSIA, 2022, 63 : 136 - 136
[6] The Impact of Disease Severity on Efficacy from a Phase 2b Study of XEN1101, A Novel Potassium Channel Opener, in Adults With Focal Epilepsy (X-TOLE)
Kenney, Christopher
French, Jacqueline
Porter, Roger
Perucca, Emilio
Brodie, Martin
Rogawski, Michael A.
Harden, Cynthia
Qian, Jenny
Beatch, Greg
NEUROTHERAPEUTICS, 2022, 19 (04) : 1427 - 1428
[7] The impact of disease severity on efficacy from a Phase 2b study of XEN1101, a novel potassium channel opener, in adults with focal epilepsy (X-TOLE)
Kenney, C.
French, J.
Porter, R.
Perucca, E.
Brodie, M.
Rogawski, M.
Harden, C.
Rosenblut, C. Luzon
Qian, J.
Leung, J.
Beatch, G.
EPILEPSIA, 2022, 63 : 136 - 136
[8] Phase 2b Efficacy and safety of XEN1101, a novel potassium channel opener, in adults with focal onset seizures (X-TOLE)
French, J.
Porter, R.
Perucca, E.
Brodie, M.
Rogawski, M.
Pimstone, S.
Aycardi, E.
Harden, C.
Xu, Y.
Rosenblut, C. Luzon
Kenney, C.
Beatch, G.
EPILEPSIA, 2022, 63 : 117 - 118
[9] Interim analysis of the long-term efficacy and safety of azetukalner in an ongoing open-label extension study following a phase 2b clinical trial (X-TOLE) in adults with focal epilepsy
French, Jacqueline A.
Porter, Roger J.
Perucca, Emilio
Brodie, Martin J.
Rogawski, Michael A.
Harden, Cynthia
Qian, Jenny
Rosenblut, Constanza Luzon
Kenney, Christopher
Beatch, Gregory N.
X-TOLE Study Grp
EPILEPSIA OPEN, 2025,
[10] Long-term, quality of life in epilepsy inventory-31 (QOLIE-31) improvements in adults with focal onset seizures treated with XEN1101 in an ongoing, open-
Brandt, C.
Villanueva, V.
Harden, C.
Qian, J.
Rosenblut, C. Luzon
Wagner, J.
Kenney, C.
Beatch, G. N.
EPILEPSIA, 2024, 65 : 183 - 184

← 1 2 3 4 5 →